Trial intelligence / Profile preview

Phase 3 study of PLB1004 versus platinum doublet chemotherapy with or without sintilimab in treatment-naive EGFR exon 20 insertion-mutant advanced non-squamous NSCLC

CTR20240057Phase 3Active

Sponsor

Anshi Pharma

Start

Mar 2024

Modality

Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules

Countries

1